Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$244.34 USD
+2.99 (1.24%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $240.10 -4.24 (-1.74%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 161 - 180 ( 185 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Who in the NASH Space Had The Best And Worst Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -NASH Weekly: If You Love NASH, You''ll Love What''s to Come at JPM Healthcare
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MGL-3196 Hits Impressive Early Data in Intern POC NASH Readout; Raise PT to $105
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MGL-3196 Hits a Home Run with Phase 2b NASH Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Clear Your Mind and Begin the Countdown; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Let''s Deep Dive and Get Smart; Affirm Buy with Increased PT
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel Mechanism for Cardiometabolic Diseases: NASH and FH; Initiate Buy, $54 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Takeaways from Our Expert Call With NASH Fibrosis Guru, Dr. Scott Friedman
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Weekly NASH Newsletter: MRI-PDFF Is The New Favorite Toy In NASH Playground
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Weekly NASH Newsletter: MRI-PDFF Is The New Favorite Toy In NASH Playground
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Is Hot and Getting Hotter! Dial-in to NASH Guru on Nov. 16 at 11:00 ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
There Is Far More To Thyroid Hormone Receptor Modulation; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Do Not Miss Our Takeaways From The Liver Meeting
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y